Risk factors and clinical consequences of interval cancers arising within faecal immunochemical testing-based colorectal cancer screening programme
BJS Open · 2025
DOI: 10.1093/bjsopen/zraf096 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJS Open, 2025. Verfasst von Adam D Gerrard und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Early Detection of Cancer, Occult Blood. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bowel Cancer UK and the Royal College of Surgeons of Edinburgh, Chief Scientist Office, Cancer Research UK.
Abstract (Originalsprache)
Background
Colorectal cancer (CRC) screening programmes aim to detect early, asymptomatic cancers and improve survival. This study aimed to establish the proportion of interval cancers, and the consequences with regard to stage, clinical outcome, and overall survival. Risk factors associated with interval CRCs were investigated.
Methods
The Scottish Bowel Screening Programme uses faecal immunochemical testing at a threshold of 80 µg haemoglobin per g as a positive trigger for investigation. Screening was offered to all eligible individuals in one region, from November 2017 to October 2021. Cancer registries were cross-checked to ensure complete capture of all cancers including interval CRCs. The primary outcome was rate of interval CRCs among participants with follow-up of 24 months, and its relationship to faecal immunochemical testing results, clinical variables, stage, time to diagnosis, and survival. The secondary outcome was identification of risk factors associated with interval CRCs.
Results
The Scottish Bowel Screening Programme generated 316 583 tests during the study period. Participation was 71.0% of the eligible population (212 664 patients); it was greater among women (71.9 versus 70.0%; P < 0.001) and in higher socioeconomic areas (76.9 versus 58.6%; P < 0.001). In the screened population, 546 CRCs were diagnosed within 2 years of screening. Some 289 of these patients (52.9%) had positive bowel screening. There were 257 patients with interval CRCs, who waited a median of 13 (interquartile range 7–20) months for diagnosis. Of CRCs diagnosed, 24.9% had screening faecal immunochemical test results of < 10 µg haemoglobin per g. The interval CRC rate was greater in women, older patients, and among the least socioeconomically deprived. Interval CRCs were associated with worse 2-year all-cause mortality than screen-detected CRCs (23.0 versus 10.8%; P < 0.001). Importantly, 121 of the 257 interval CRCs (47.1%) had detectable faecal immunochemical test results at 10–79 µg haemoglobin per g.
Conclusion
Patients with interval CRCs and a detectable faecal immunochemical test result below the predetermined threshold appear to be significantly disadvantaged with respect to stage at presentation and survival. Almost half of interval CRCs diagnosed within 2 years had detectable haemoglobin on screening faecal immunochemical test and would be a target for lower positivity thresholds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
- Department of Colorectal Surgery, Western General Hospital, Edinburgh, UK.
- Department of Surgery, Queen Elizabeth University Hospital, Glasgow, UK.
- Lothian Analytical Services, NHS Lothian, Edinburgh, UK.
- Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK.
- UK Colon Cancer Genetics Group, Medical Research Council Human Genetics Unit, Medical Research Council Institute of Genetics and Cancer, Western General Hospital, University of Edinburgh, Edinburgh, UK.
ORCID-Profile: Adam D Gerrard, Yasuko Maeda, Malcolm G Dunlop
Förderung
- Bowel Cancer UK and the Royal College of Surgeons of Edinburgh
- Chief Scientist Office
- Cancer Research UK
- Scottish Government
- Cancer Research UK programme grant
- CRUK Career Development Fellowship
Zitieren
APA
Gerrard, A. D., Garau, R., Maeda, Y., Thomson, A., Theodoratou, E., Dunlop, M. G., & Din, F. V. N. (2025). Risk factors and clinical consequences of interval cancers arising within faecal immunochemical testing-based colorectal cancer screening programme. BJS Open. https://doi.org/10.1093/bjsopen/zraf096
Vancouver
Gerrard AD, Garau R, Maeda Y, Thomson A, Theodoratou E, Dunlop MG, et al. Risk factors and clinical consequences of interval cancers arising within faecal immunochemical testing-based colorectal cancer screening programme. BJS Open. 2025. doi:10.1093/bjsopen/zraf096
BibTeX
@article{Gerrard2025,
author = {Gerrard, Adam D and Garau, Roberta and Maeda, Yasuko and Thomson, Alastair and Theodoratou, Evropi and Dunlop, Malcolm G and Din, Farhat V N},
title = {Risk factors and clinical consequences of interval cancers arising within faecal immunochemical testing-based colorectal cancer screening programme},
journal = {BJS Open},
year = {2025},
doi = {10.1093/bjsopen/zraf096}
}
EUVIMED